Fluticasone propionate via the Diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacholine-induced airway hyperresponsiveness

Chest

Volumn 122, Issue 3, 2002, Pages 806-811

  Langley, Stephen J ^a   Holden, Janet ^a   Derham, Alison ^a   Hedgeland, Paul ^b   Sharma, Raj K ^b   Woodcock, Ashley ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Diskhaler; Fluticasone propionate; Hydrofluoroalkane 134a; Methacholine; Placebo; Provocative dose of methacholine causing a 20 fall in FEV1

Indexed keywords

FLUTICASONE PROPIONATE; HYDROCORTISONE; METHACHOLINE; NORFLURANE; PLACEBO;

ADULT; ARTICLE; ASTHMA; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; GEOMETRY; HOARSENESS; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUNG FUNCTION; MALE; METERED DOSE INHALER; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; THROAT DISEASE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 0036385721     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.122.3.806     Document Type: Article

References (24)

1. Hargreave FE, Dolovich J, O'Byrne PM, et al. The origin of airway hyperresponsiveness. J Allergy Clin Immunol 1986; 78:825-832
2. Sterk PJ, Bel EH. The shape of the dose-response curve to inhaled bronchoconstrictor agents in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143:1433-1437
3. Boushey HA, Holtzman MJ. Experimental airway inflammation and hyperreactivity. Am Rev Respir Dis 1985; 131:312-313
4. Noonan MJ, Chervinsky P, Wolfe J, et al. Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study. J Asthma 1998; 35:153-164
5. Bootsma GP, Dekhuijzen PNR, Festen J, et al. Comparison of fluticasone propionate and beclomethasone propionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Thorax 1995; 50:1044-1050
6. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145:669-674
7. Westbroek J, Pasma HR. Effects of 2 weeks of treatment with fluticasone propionate 100 μg b.d. by comparison with zafirlukast 20mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma. Respir Med 2000; 94:112-118
8. Lundbäck R, Dahl R, DeJonghe M, et al. A comparison of fluticasone propionate when delivered by either the metered-dose inhaler or the Diskhaler inhaler in the treatment of mild to moderate asthma. Eur J Clin Res 1994; 5:11-19
9. Cripps A, Riebe M, Schulze M, et al. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000; 94(suppl B):3-9
10. Stone DWG, Jaiswal BK, Mairs ML, et al. Clinical efficacy and safety of fluticasone propionate 100 μg twice daily administered via a hydrofluoroalkane metered dose inhaler to patients with mild to moderate asthma. Clin Drug Invest 2001; 21:695-703
11. Tonnel AB, Bons J, Legendre M, et al. Clinical efficacy and safety of fluticasone propionate 250 μg twice daily administered via a HFA 134a pressurised metered dose inhaler to patients with mild to moderate asthma. Respir Med 2000; 94(suppl B):29-34
12. Perruchoud AP, Lundback B, Yigla Y, et al. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. Respir Med 2000; 94(suppl B):35-41
13. Ayres JG, Miller AB, Sykes AP. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. Respir Med 2000; 94(suppl B):42-50
14. Custovic A, Taggart SCO, Stuart A, et al. Efficacy of a new non-ozone depleting formulation for salbutamol. J Pharm Med 1995; 5:161-168
15. Busse W, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104:1215-1222
16. Lündback B, Alexander M, Day J, et al. Evaluation of fluticasone propionate (500 μg day-1) administered as either a dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 μg day-1) administered by pressurized inhaler. Respir Med 1993; 87:609-617
17. Simpson A, Custovic A, Pipis A, et al. A single centre randomized placebo-controlled, double-blind, double-dummy, three way crossover study to compare the effect of beclomethasone dipropionate 400 μg twice daily for four weeks delivered via the Diskus/Accuhaler or MDI and placebo on PD20 FEV1 (methacholine) in patients with reversible airways disease [abstract]. Eur Respir J 1998; 12(suppl 28):365
18. Yan K, Salome C, Woolcock AJ. Rapid measurement of bronchial hyper-responsiveness. Thorax 1983; 38:760-765
19. Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313:36-39
20. Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994; 94:676-683
21. Senn S. Cross-over clinical trials in clinical research. Chich-ester, UK: Wiley, 1993
22. Kraan J, Koeter GH, van den Mark TW, et al. Changes in bronchial hyperrreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76:628-636
23. Hofstra WB, Neijens HJ, Duiverman EJ, et al. Dose-responses over time to inhaled fluticasone propionate treatment of exercise and methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol 2000; 29:415-423
24. Pearlman DS, Noonan MJ, Tashkin DP, et al. Comparative efficacy and safety of twice daily fluticasone propionate powder vs placebo in the treatment of moderate asthma. Ann Allergy Asthma Immunol 1997; 78:356-362